Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + entecavir
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Peginterferon alfa-2a + entecavir is a combination therapy used primarily in the treatment of chronic hepatitis B and has been studied for chronic hepatitis D. Peginterferon alfa-2a is a pegylated recombinant form of interferon alpha that exerts both immunomodulatory and antiviral effects by binding to type 1 interferon receptors, leading to activation of intracellular signaling pathways that enhance the immune response against viral infections[1][6]. Entecavir is a potent nucleoside analogue that selectively inhibits hepatitis B virus (HBV) polymerase, blocking three key steps in HBV DNA replication: priming, reverse transcription of negative-strand DNA, and synthesis of positive-strand DNA[5]. The combination aims to improve virologic response rates by targeting different aspects of viral replication and host immunity. This regimen has been evaluated for efficacy and safety in patients with chronic HBV infection (including pediatric populations) as well as in clinical trials for chronic hepatitis D; however, some studies have shown limited additional benefit over monotherapy with peginterferon[4][5].
- Brand names
- PegasysBaraclude
- Other names
- PEG-IFNα-2a + entecavirPegasys + entecavir
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on peginterferon alfa-2a + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + entecavir.